Extended Data Fig. 4: mt-Ogg1 prevents pristane-induced B6 autoimmunity.

8-week-old wild-type (WT) and mt-Ogg1Tg females (B6 background) were given a single i.p. injection of 0.5 ml PBS or pristane and analyzed 12 months later. a, Serum titers of anti-dsDNA IgG. b, Serum IL-1β amounts. c, Spleen mass to body weight ratio. d, Percentages of splenic GC B, Tfh and IgG1+IgM-CD19+ B cells. e, Sizes of glomeruli (n = 112/WT PBS, n = 91/WT Pristane, n = 107/mt-Ogg1Tg PBS, n = 100/mt-Ogg1Tg Pristane), MFI quantitation of IgG (n = 81/WT PBS or Pristane, n = 102/mt-Ogg1Tg PBS, n = 85/mt-Ogg1Tg Pristane) and C3 deposits (n = 81/WT PBS, n = 89/WT Pristane, n = 95/mt-Ogg1Tg PBS, n = 88/mt-Ogg1Tg Pristane) and CD45+ cell areas % (n = 31/WT PBS, n = 28/WT Pristane, n = 41/mt-Ogg1Tg PBS, n = 40/mt-Ogg1Tg Pristane) in kidney sections. f, Relative amounts of serum ccf-mtDNA. g, Serum non-Ox-mtDNA (Fpg-resistant). h, Serum nDNA (Tert or B2m) to mtDNA (D-loop) ratio. Results are mean ± SD. n = 4/group (a-d and f-h). Two-way ANOVA with Tukey multiple-comparison test.